Leadership team Kate Priestman BA (Hon) Age 51 Chief Corporate & External Affairs Officer Kate Priestman was named Chief Corporate & External Affairs Officer in September 2023. In this role Kate is accountable for building and enhancing CSL’s relationships with governments and other key external stakeholder groups to enable unconstrained access to CSL’s transformational medicines and maintain its reputation and influence as a market‑leading global innovator continues to grow. Kate has over 25 years’ experience in the biopharma industry, having served in a series of commercial and corporate leadership roles across the sector. Dave Ross BA (Finance) MBA Age 58 Senior Vice President and General Manager CSL Seqirus Dave Ross was named Senior Vice President and General Manager of CSL Seqirus in April 2024. With more than 35 years of cross‑functional experience, Dave brings proven leadership skills to CSL Seqirus’ mission of delivering pioneering vaccine solutions to people around the world. Prior to his current position, Dave spent seven years as CSL Seqirus’ Vice President of Commercial Operations – North America. Under his leadership, Dave led his team to achieve significant and consistent revenue growth in North America while outperforming the competition through the implementation of CSL Seqirus’ Differentiation Strategy. Andy Schmeltz BA (Economics) MBA (Marketing & Finance) Age 54 Executive Vice President, CSL Behring Andy was appointed Executive Vice President, CSL Behring in June 2023. He is responsible for the CSL Behring business spanning plasma collection, portfolio development and commercialisation of medicines around the world. Andy is an established cross‑functional healthcare leader who has held various roles across multiple disciplines during his thirty years in the industry. Andy joined CSL from Pfizer where he was the Head of enterprise‑wide Commercial Strategy & Innovation. 48 Governance
RkJQdWJsaXNoZXIy MjE2NDg3